Paper Details
- Home
- Paper Details
Response of MUTZ-3 dendritic cells to the different components of the Haemophilus influenzae type B conjugate vaccine: towards an in vitro assay for vaccine immunogenicity.
Author: HoefnagelMarcel H N, ScheperRik J, VandebrielRob J, VermeulenJolanda P
Original Abstract of the Article :
Potency testing is mandatory for vaccine registration and batch release. Due to various limitations to in vivo potency testing, there is need for relevant in vitro alternatives. These alternative tests should preferably comprise cells from the target (human) species. The whole suite of immune respon...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.vaccine.2011.05.050
データ提供:米国国立医学図書館(NLM)
Unlocking Vaccine Immunogenicity: Evaluating the Response of MUTZ-3 Dendritic Cells to Haemophilus influenzae Type B Vaccine Components
This research explores the potential of an in vitro assay using MUTZ-3 dendritic cells (DCs), a human cell line, to assess the immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccine. DCs, as important orchestrators of the immune response, are a promising candidate cell type for in vitro assays. The study compared the response of MUTZ-3 DCs to monocyte-derived DCs (moDCs), evaluating their responses to different vaccine components, including the Hib antigen (PRP), outer membrane protein (OMP), conjugated PRP-OMP, and the adjuvanted vaccine (PedVax HiB). The results showed that MUTZ-3 DCs responded consistently to different vaccine components, demonstrating their potential as a reliable in vitro model for assessing vaccine immunogenicity.Moving Beyond Animal Testing: The Quest for In Vitro Immunogenicity Assays
This research highlights the importance of developing in vitro assays to evaluate vaccine immunogenicity, reducing the reliance on animal testing. MUTZ-3 DCs, as a stable and reproducible human cell line, offer a promising alternative for assessing vaccine effectiveness.The Future of Vaccine Development: A Blend of In Vitro and In Vivo Techniques
While in vitro assays are valuable tools for assessing vaccine immunogenicity, they cannot completely replace in vivo testing. However, by combining in vitro and in vivo approaches, researchers can develop more robust and comprehensive methods for evaluating vaccine efficacy.Dr. Camel's Conclusion
This study represents a significant step towards developing more efficient and ethical methods for evaluating vaccine immunogenicity. Just as a camel can find water in the desert by relying on both its physical senses and its knowledge of the environment, researchers are utilizing a combination of in vitro and in vivo approaches to understand and optimize the efficacy of vaccines.Date :
- Date Completed 2012-01-18
- Date Revised 2011-07-18
Further Info :
Related Literature
Article Analysis
SNS
PICO Info
in preparation
Languages
English
Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.